NCT01598493

Brief Summary

Background: Bio-medical Carbon Technology (BCT) Antimicrobial Dressing, a novel advanced wound dressing invented by Bio-medical Carbon Technology Co., Ltd., Taiwan, consists principally of activated carbon fiber impregnated with silver particles. The highly porous nature and the large specific surface area of activated carbon fiber provide a tremendous adsorptive capacity for toxins, wound degradation products, and odors. Furthermore, far infrared ray emitted from activated carbon fiber accelerates blood circulation to stimulate tissue regeneration. Silver ions efficiently eliminate a broad spectrum of bacteria through penetrating the cell wall of bacteria and denaturing essential proteins. This clinical trial investigates wound healing effects of BCT Antimicrobial Dressing on deep dermal burn patients. Aim: To investigate wound healing effects of BCT Antimicrobial Dressing on deep dermal burn. Methods: This trial is expected to recruit 30 eligible subjects. After hospitalized patients are diagnosed as deep dermal burn, the procedure of Informed Consent is conducted by the project investigator. As long as the patient agrees to join this clinical trial and signs the Informed Consent, two separate areas of 25 cm2 in the same anatomic site are chosen and distributed to the control and research groups respectively by coin flipping. The wound in the research group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days (counting from the day applied BCT dressings: Day0, 3, 6, 9, 12, 15……etc.) until the wound is healed. Flamazine is applied on the wound in the control group instead and then covered with sterile gauze, and the frequency of dressing change is daily until the wound is recovered. The healed and non-healed area of wound is recorded and photographed every 3 days, and the wound color and infection are also evaluated. On Day 12 and Day 21, compare the ratio of healing and non-healed areas in the control and research groups, and the ending point is set on the 21st day. Statistics Analysis: Paired Student's t-test will be performed to analyze the clinical data by comparing the difference of the healing percentage, the healing rate, the infection rate, and the frequency of dressing change. It is statistically significant when P\<0.05.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

May 9, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 15, 2012

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
Last Updated

July 13, 2017

Status Verified

July 1, 2017

Enrollment Period

1.8 years

First QC Date

May 9, 2012

Last Update Submit

July 12, 2017

Conditions

Keywords

BurnsWound Healing

Outcome Measures

Primary Outcomes (1)

  • The healing rate

    Photograph of wounds are taken on the specific day (Day0, 3, 6, 9……etc.) and pictures are imported to image-analyzing software for the calculation of wound area. And the number of wound area is then transformed to the healing percentage. Healing Rate= healed area/the number of healing days (cm2/day)

    21 days

Secondary Outcomes (2)

  • The healing percentage

    21 days

  • The size of skin-grafting area

    21 days

Study Arms (2)

Control

ACTIVE COMPARATOR

Flamazine is applied on the wound in the control group instead and then covered with sterile gauze

Drug: Flamazine

BCT Antimicrobial Dressing

EXPERIMENTAL

The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.

Device: BCT Antimicrobial Dressing

Interventions

Activated carbon fiber impregnated with silver particles

BCT Antimicrobial Dressing

Silver sulfadiazine cream

Control

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The total burn area is between 5% to 30%
  • Male/Female of any race aged between 20 - 80 years old
  • Non taking any medicine containing steroid
  • No allergy to activated carbon fiber and silver
  • No history of cardiovascular diseases, diabetes mellitus, immune system-related diseases, hepatic disease, hematic diseases, renal diseases, and cancer

You may not qualify if:

  • The total burn area is less than 5% or larger than 30%
  • Male/Female of any race aged younger than 20 years old or older than 80 years old
  • Taking any medicine containing steroid
  • Allergy to activated carbon fiber and silver
  • With history of cardiovascular diseases, diabetes mellitus, immune system-related diseases, hepatic disease, hematic diseases, renal diseases, and cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Burn Center, Department of Surgery, National Taiwan University Hospital

Taipei, 10002, Taiwan

Location

MeSH Terms

Conditions

Burns

Interventions

Silver Sulfadiazine

Condition Hierarchy (Ancestors)

Wounds and Injuries

Intervention Hierarchy (Ancestors)

SulfadiazineBenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsSulfanilamidesAniline CompoundsAminesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur Compounds

Study Officials

  • Eng Kean Yeong, MD

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2012

First Posted

May 15, 2012

Study Start

May 1, 2012

Primary Completion

March 1, 2014

Study Completion

March 1, 2014

Last Updated

July 13, 2017

Record last verified: 2017-07

Locations